DRW Securities’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$242K Buy
25,697
+2,090
+9% +$18.7K 0.01% 707
2026
Q1
$192K Buy
23,607
+11,707
+98% +$106K ﹤0.01% 1129
2025
Q4
$80K Sell
11,900
-7,034
-37% -$53K ﹤0.01% 1086
2025
Q3
$164K Buy
+18,934
New +$147K ﹤0.01% 1121
2021
Q2
– Sell
-5,600
Closed -$1.01M – 337
2021
Q1
$1.01M Buy
+5,600
New +$1.12M 0.04% 90

Other funds holding NVAX

DRW Securities's NVAX Position: Q2 2026 in Review

DRW Securities increased its Novavax (NVAX) stake by 8.9% in Q2 2026, buying an estimated $18.7K and bringing the position to 25,697 shares worth $242K. The position accounts for 0.01% of the portfolio, ranked #707.

DRW Securities first reported a position in NVAX in Q1 2021 and has held it in 5 quarters since. The position peaked at $1.01M in Q1 2021. 268 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • DRW Securities held 25,697 shares of Novavax worth $242K as of Q2 2026.
  • DRW Securities bought 2,090 Novavax shares in Q2 2026, an estimated $18.7K.
  • Novavax made up 0.01% of DRW Securities's portfolio in Q2 2026, its #707 holding.
  • DRW Securities first reported a position in Novavax in Q1 2021 and has held it in 5 quarters since.
  • DRW Securities's Novavax position peaked at $1.01M in Q1 2021.
  • 268 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on DRW Securities's 13F filing for Q2 2026, filed 14 Aug 2026.